 Biocept Inc NASDAQ:BIOC FRA:B003 announced the full commercial launch of CNSide, the companys cerebrospinal fluid CSF assay designed to better detect and manage the treatment of metastatic cancers involving the central nervous system CNS. The company said the assay, which was initially introduced in January 2020, has the ability to offer a timely and accurate method to diagnose disease, identify actionable biomarkers, and assess response to therapy, potentially impacting life expectancy and quality of life. 